[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
..
Publication Charge
►Publication Fee
..
In Press
 In Press Articles
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 7, Issue 1 (1-2016) ::
Caspian J Intern Med 2016, 7(1): 19-24 Back to browse issues page
Comparison of Pyridostigmine and bisacodyl in treatment of refractory chronic constipation.
Iman Soufi-Afshar , Aliakbar Moghadamnia , Ali Bijani , Sohrab Kazemi , Javad Shokri-Shirvani
Department of internal Medicine, Babol University of Sciences, Babol, Iran , javadshokry@gmail.com
Abstract:   (9294 Views)

Background: Treatment of chronic constipation is creating one of the major problems for doctors and patients. Pyridostigmine increases the gastrointestinal motility through the effects on cholinesterase. It seems that this mechanism can reduce chronic constipation. The aim of this study was to compare the effects of pyridostigmine and bisacodyl on chronic constipation.

Methods: This study was conducted on 68 patients who suffered from chronic constipation. Patients were randomly divided into two groups of Pyridostigmine and bisacodyl in which each consisted of 34 patients, respectively. Bristol stool form score, straining defecation, the time of defecation, the number of defecation per week, sense of incomplete evacuation and self-digitation were collected by means of questionnaires and the data were compared.

Results: Sixty-eight patients with the mean age of 68.12±84.49 were studied. The mean difference in the frequency of defecation per week, VAS score, the time to defecation and the Bristol Stool form Scale in pre and post-treatment were 4.33±1.88, 5.96±2.29, 12.30±7.95 min and 2.10±0.95 in pyridostigmine group and 2.96±1.81, 4.06±2.22, 6.67±5.23 min and 1.41±0.84 in bisacodyl group, respectively. The significant difference was observed in both pyridostigmine and bisacodyl groups (P=0.005, P=0.002, P=0.002 and P=0.005, respectively). 60% and 32.3 of patients in pyridostigmine and bisacodyl groups recovered from self-digitations, respectively. In pyridostigmine and bisacodyl groups, 66.7% and 32.3 of them had improvement in the sense of incomplete defecation, respectively.

Conclusion: Pyridostigmine and bisacodyl significantly improved the symptoms of chronic constipation similarly.

Keywords: Constipation, chronic constipation, anti-cholinesterase, pyridostigmine
Full-Text [PDF 301 kb]   (2027 Downloads)    
Type of Study: Original Article | Subject: Gastroentrology
Received: 2015/02/3 | Accepted: 2015/02/23 | Published: 2015/09/13
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Soufi-Afshar I, Moghadamnia A, Bijani A, Kazemi S, Shokri-Shirvani J. Comparison of Pyridostigmine and bisacodyl in treatment of refractory chronic constipation.. Caspian J Intern Med 2016; 7 (1) :19-24
URL: http://caspjim.com/article-1-472-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7, Issue 1 (1-2016) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4645